COVID-19 Clinical Trial
Official title:
Determination of Dornase Alpha Effectiveness in COVID-19 Treatment
In this study, the effectiveness of the Dornase Alpha treatment, which is known to reduce the viscosity of respiratory secretions, will be investigated in new diagnosed and severe COVID-19 patients separately.
Recent studies confirmed the role of immune hyperactivation in the pathogenesis of COVID-19.
Immune cells, especially neutrophils, infiltrate pulmonary capillaries that cause acute
fibrin deposition and extravasation into the alveolar space. This excessive accumulation of
neutrophils constitutes NETs which makes the mucus thick and viscous. The highly viscous
mucus lowers the patient's respiratory function and impairs ventilation supporting NETs may
play a major role in the disease. As a mechanism, double-stranded DNA constitutes the
backbone of NETs and Dornase alfa promotes the clearance of NETs from plasma neutralization.
Endogenous Deoxyribonucleases (DNases), which physiologically break up this extracellular
DNA, may become overwhelmed by a massive influx of NETs. Clinically, recombinant human DNase
I (rhDNase, Dornase Alfa) has the identical primary amino acid sequence with the native human
enzyme and has been approved for the management of cystic fibrosis. Daily administration of
dornase alfa is effective in the treatment of cystic fibrosis patients improving pulmonary
functions. The similarity of mucus secretions in COVID-19 and cystic fibrosis patients by the
means of NETs makes Dornase alfa as a therapeutic option in COVID-19.
Progressive COVID-19 pneumonia may be mortal if it is not treated early, causing respiratory
failure. The most important factor leading to respiratory failure is hyaline membrane formed
by a neutrophil trap that develops in the cavities of the alveoli. Dornase Alpha is thought
to have an important contribution by the lysis of this hyalen membrane. In this study, it is
aimed to evaluate the effectiveness of Dornase Alpha treatment in case of early and late use
in COVID-19 disease.
Patients diagnosed with COVID-19 PCR and / or radiological-clinical findings is included in
the study, and this treatment is carried out in 2 patient groups in comparison with the
control groups. The groups are:
1. Newly Diagnosed Patient Group I. Dornase Alpha treated group ii. Control group
2. Patient Group Monitored by Mechanical Ventilation I. Dornase Alpha treated group ii.
Control group
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT06065033 -
Exercise Interventions in Post-acute Sequelae of Covid-19
|
N/A | |
| Completed |
NCT06267534 -
Mindfulness-based Mobile Applications Program
|
N/A | |
| Completed |
NCT05047601 -
A Study of a Potential Oral Treatment to Prevent COVID-19 in Adults Who Are Exposed to Household Member(s) With a Confirmed Symptomatic COVID-19 Infection
|
Phase 2/Phase 3 | |
| Recruiting |
NCT05323760 -
Functional Capacity in Patients Post Mild COVID-19
|
N/A | |
| Recruiting |
NCT04481633 -
Efficacy of Pre-exposure Treatment With Hydroxy-Chloroquine on the Risk and Severity of COVID-19 Infection
|
N/A | |
| Completed |
NCT04537949 -
A Trial Investigating the Safety and Effects of One BNT162 Vaccine Against COVID-19 in Healthy Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT04612972 -
Efficacy, Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccines (Vero Cell) to Prevent COVID-19 in Healthy Adult Population In Peru Healthy Adult Population In Peru
|
Phase 3 | |
| Recruiting |
NCT05494424 -
Cognitive Rehabilitation in Post-COVID-19 Condition
|
N/A | |
| Active, not recruiting |
NCT06039449 -
A Study to Investigate the Prevention of COVID-19 withVYD222 in Adults With Immune Compromise and in Participants Aged 12 Years or Older Who Are at Risk of Exposure to SARS-CoV-2
|
Phase 3 | |
| Enrolling by invitation |
NCT05589376 -
You and Me Healthy
|
||
| Completed |
NCT05158816 -
Extracorporal Membrane Oxygenation for Critically Ill Patients With COVID-19
|
||
| Recruiting |
NCT04341506 -
Non-contact ECG Sensor System for COVID19
|
||
| Completed |
NCT04512079 -
FREEDOM COVID-19 Anticoagulation Strategy
|
Phase 4 | |
| Completed |
NCT04384445 -
Zofin (Organicell Flow) for Patients With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05975060 -
A Study to Evaluate the Safety and Immunogenicity of an (Omicron Subvariant) COVID-19 Vaccine Booster Dose in Previously Vaccinated Participants and Unvaccinated Participants.
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT05542862 -
Booster Study of SpikoGen COVID-19 Vaccine
|
Phase 3 | |
| Terminated |
NCT05487040 -
A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease
|
Phase 1 | |
| Withdrawn |
NCT05621967 -
Phonation Therapy to Improve Symptoms and Lung Physiology in Patients Referred for Pulmonary Rehabilitation
|
N/A | |
| Terminated |
NCT04498273 -
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
|
Phase 3 | |
| Active, not recruiting |
NCT06033560 -
The Effect of Non-invasive Respiratory Support on Outcome and Its Risks in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2)-Related Hypoxemic Respiratory Failure
|